Instrument Inactif

Communiqués GRI Bio, Inc.

Actions

GRI

US3622AW2059

Cours en clôture Nasdaq Autres places de cotation 00:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
0,4007 ^USD	-1,18%		+2,72%	-85,13%

21/05	GRI Bio, Inc. présente des données précliniques positives de son portefeuille de modulateurs de cellules NKT en développement pour le traitement du lupus érythémateux systémique.	CI
20/05	GRI Bio, Inc. GRI Bio présente des données précliniques positives démontrant que son programme phare GRI-0621 réduit les facteurs inflammatoires et fibrotiques importants dans la fibrose pulmonaire idiopathique (FPI)	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GRI Bio Announces Reverse Stock Split	26/01	AQ
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment	06/12	AQ
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	05/12	AQ
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	27/11	AQ
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	15/11	AQ
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	31/10/23	AQ
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	19/10/23	AQ
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	17/10/23	AQ
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference	11/10/23	AQ
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions	05/10/23	AQ
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference	06/09/23	AQ
GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign	29/08/23	NE
Thinking about buying stock in MicroCloud Hologram, AgileThought, GRI Bio, Profire Energy, or Foot Locker?	24/08/23	PR
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR	23/08/23	AQ
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update	14/08/23	AQ
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models	07/08/23	AQ
GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference	03/08/23	AQ
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event	24/07/23	AQ
DEVONIAN HEALTH GROUP ANNOUNCES THE APPOINTMENT OF NEW BOARD MEMBERS AND GRANT OF STOCK OPTIONS	15/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Les meilleurs outils réservés aux abonnés pour augmenter la performance de vos investissements !

Optimiser mes Profits

fermer